Diabetes drug metformin inhibits multidrug-resistant breast cancer

December 6, 2017

The drug metformin, typically prescribed to treat type 2 diabetes, keeps breast cancer cells from developing multiple drug resistance (MDR) and can reverse MDR after it¹s appeared, according to a study published December 6, 2017 in the open-access journal PLOS ONE by Terra Arnason from the University of Saskatchewan, Canada, and colleagues.

Previous studies have shown that metformin has some antiproliferative activity against multiple types of cancer cells. Moreover, clinical meta-analysis studies on cancer patients who already take metformin to treat diabetes have hinted that the drug may boost their survival and prevent the emergence of new tumors.

Arnason and colleagues probed the effect of metformin on the widely studied cell line MCF7. Metformin, they found, had an antiproliferative effect on MCF7, including cells that were resistant to the common chemotherapeutic Doxorubicin. When cells were pretreated with metformin, the development of drug resistance was prevented or delayed. In addition, experiments conducted in both cell cultures and mouse models of aggressive breast cancer revealed that metformin reversed protein markers associated with MDR after its onset.

These findings establish that metformin has the potential to both reverse MDR in cell lines and prevent its onset. Future research will need to extend the timeline of the study to follow for many months and determine if the effect of is permanent or short-lived.

Explore further: Metformin use does not increase prostate cancer survival

More information: Gerald Davies et al, Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer, PLOS ONE (2017). DOI: 10.1371/journal.pone.0187191

Related Stories

Metformin use does not increase prostate cancer survival

April 11, 2017
(HealthDay)—Metformin use in combination with docetaxel chemotherapy does not significantly improve survival in patients with diabetes and metastatic castration-resistant prostate cancer, according to a study published ...

Prevalence of metformin use 0.7 percent in prediabetes

April 7, 2017
(HealthDay)—For U.S. adults with prediabetes, the prevalence of metformin use is 0.7 percent, according to a study published online April 3 in Diabetes Care.

Metformin therapeutic as post-ischemic conditioning agent

June 29, 2017
(HealthDay)—Metformin has therapeutic potential as a post-ischemic conditioning agent, according to a study published online June 23 in Cardiovascular Therapeutics.

Metformin use linked to less vitamin B12 measurement

February 17, 2017
(HealthDay)—Long-term metformin use is associated with lower serum vitamin B12 concentration, although metformin users are less likely to receive vitamin B12 testing, according to a study published online Feb. 9 in the ...

Common diabetes drug may help treat ovarian cancer

December 3, 2012
A new study suggests that the common diabetes medication metformin may be considered for use in the prevention or treatment of ovarian cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer ...

Metformin confers anti-tumor immunity by reactivating exhausted CD8T lymphocytes

February 24, 2016
Anti-cancer effect of tumor infiltrating CD8+T lymphocyte (CD8TIL) is suppressed by interaction between immune-checkpoint molecules such as PD-1 and CTLA-4 expressed on CD8TIL and their ligands expressed on cancer cells, ...

Recommended for you

One in five young colon cancer patients have genetic link

December 13, 2017
As doctors grapple with increasing rates of colorectal cancers in young people, new research from the University of Michigan may offer some insight into how the disease developed and how to prevent further cancers. Researchers ...

New strategy for unleashing cancer-fighting power of p53 gene

December 13, 2017
Tumor protein p53 is one of the most critical determinants of the fate of cancer cells, as it can determine whether a cell lives or dies in response to stress. In a new study published today in the journal Nature Communications, ...

Researchers develop test that can diagnose two cancer types

December 12, 2017
A blood test using infrared spectroscopy can be used to diagnose two types of cancer, lymphoma and melanoma, according to a study led by Georgia State University.

Cancer-causing mutation suppresses immune system around tumours

December 12, 2017
Mutations in 'Ras' genes, which drive 25% of human cancers by causing tumour cells to grow, multiply and spread, can also protect cancer cells from the immune system, finds a new study from the Francis Crick Institute and ...

Atoh1, a potential Achilles' heel of Sonic Hedgehog medulloblastoma

December 12, 2017
Medulloblastoma is the most common type of solid brain tumor in children. Current treatments offer limited success and may leave patients with severe neurological side effects, including psychiatric disorders, growth retardation ...

MRI scans predict patients' ability to fight the spread of cancer

December 12, 2017
A simple, non-invasive procedure that can indicate how long patients with cancer that has spread to the brain might survive and whether they are likely to respond to immunotherapy has been developed by researchers in Liverpool.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.